EMA suggests restructuring eCTD to facilitate public access to documents
This article was originally published in SRA
The European Medicines Agency wants drug regulatory authorities around the world to work towards restructuring the current eCTD (electronic common technical document) submission format to better enable redacting of commercially confidential information from these submissions so that they can be made available to the public1.
You may also be interested in...
Days after a senior Chinese government official offered free COVID-19 vaccines to the Philippines government, the country’s medicines regulator said the donated jabs would need an emergency approval before they can be used on the public.
The European Directorate for the Quality of Medicines & HealthCare is proceeding carefully to find the right balance between serving the diverse requirements of various stakeholders that make use of its ‘certificates of suitability.’
The International Pharmaceutical Regulators Programme has documented various approaches currently being used for the clinical comparability of biosimilar monoclonal antibodies in different jurisdictions.